$2.43
N/A
Last update: Nov 10, 4:00 AM
Alterity Therapeutics Ltd
ATHENASDAQ
Alterity Therapeutics fell 34.7% from $3.72 to $2.43, behind the S&P 500's +10.5%. Its worst day was May 15 (−14.1%), and its low came Oct 23 at $2.03.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced…
+13.7% · S&P 500 −0.3%
Story events cover the past 12 months · Times ET
Alterity Therapeutics shares rose 19.5%, while the S&P 500 fell 0.2%.
+19.5%, the year's best day · S&P 500 −0.2%
Alterity Therapeutics shares fell 14.1%, while the S&P 500 fell 1.2%.
−14.1%, the year's worst day · S&P 500 −1.2%
Alterity Therapeutics closed at its highest level of the year, 58.3% above where the year started.
+9.9% · S&P 500 +0.9%
Alterity Therapeutics closed at its lowest level of the year, 45.4% below where the year started.
−5.6% · S&P 500 −0.5%
Alterity Therapeutics shares rose 18.2%, while the S&P 500 rose 0.3%.
+18.2%, on 4M shares, the year's heaviest volume · S&P 500 +0.3%
Where it ended: a close of $2.43 on Nov 9, 2026.
Nothing in the past 12 months.
All ATHE earningsNothing in the past 12 months.
All ATHE dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ATHE and SPY from Benzinga historical bars. Not investment advice.
